Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Klisyri for sun-damaged skin on the face
NCT05900258Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tirbanibulin in actinic keratosis (AK), sponsored by Medical University of Graz. Primary endpoint: Unmasking of subclinical lesions in UV-exposed areas of chronically sun-damaged skin of the face at 57 days. Started May 2023; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT05900258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900258.